| Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell Carcinoma (NCT04961320) | City of Hope Medical Center | 2022-07-15 |
| A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC). (NCT05858749) | Pfizer | 2022-06-20 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (NCT05092373) | M.D. Anderson Cancer Center | 2022-04-29 |
| Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma (NCT04919122) | Duke University | 2022-04-01 |
| Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative Therapy (NCT05112627) | Mayo Clinic | 2022-01-24 |
| Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors (NCT05263050) | Fox Chase Cancer Center | 2022-01-21 |
| Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma (NCT05135832) | Herlev and Gentofte Hospital | 2021-12-13 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer (NCT05122546) | City of Hope Medical Center | 2021-11-01 |
| A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma (NCT05119335) | NiKang Therapeutics, Inc. | 2021-10-26 |
| Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer (NCT04603365) | Jonsson Comprehensive Cancer Center | 2021-10-18 |
| App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients With Metastatic Renal Cell Cancer (NCT04788095) | City of Hope Medical Center | 2021-08-23 |
| Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery (NCT04588246) | NRG Oncology | 2021-08-05 |
| Measuring Treatment Response in Metastatic Renal Cell Cancer Using FPIA PET/CT (NCT04802824) | Imperial College London | 2021-05-25 |
| The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma (NCT04262427) | The Christie NHS Foundation Trust | 2021-04-28 |
| Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial (NCT04693377) | M.D. Anderson Cancer Center | 2021-03-16 |
| Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial (NCT04510597) | SWOG Cancer Research Network | 2021-03-08 |
| Urine Omics Predicting IO Therapy Responses in mRCC Patients (NCT04712305) | National Taiwan University Hospital | 2021-01-04 |
| Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC) (NCT04508725) | Stanford University | 2020-12-05 |
| Cancer and Blood Pressure Management, CARISMA Study (NCT04467021) | ECOG-ACRIN Cancer Research Group | 2020-10-29 |
| Nivolumab Plus Metformin in Metastatic Renal Cell Carcinoma (NCT06884683) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2020-09-17 |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (NCT04140526) | OncoC4, Inc. | 2020-09-16 |
| PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer (NCT03927248) | HealthPartners Institute | 2020-09-01 |
| A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases (NCT04299646) | Centre Francois Baclesse | 2020-07-01 |
| Retrospective Study on the Safety of Nivolumab in Patients With mRCC and Renal Failure (NCT07117409) | Azienda USL Reggio Emilia - IRCCS | 2020-06-29 |
| Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer (NCT04337970) | Memorial Sloan Kettering Cancer Center | 2020-04-06 |
| Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma (NCT04644432) | Herlev and Gentofte Hospital | 2020-03-06 |
| SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (NCT04090710) | Ontario Clinical Oncology Group (OCOG) | 2020-01-29 |
| Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma (NCT04068831) | Memorial Sloan Kettering Cancer Center | 2019-08-22 |
| Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma (NCT04049344) | Zhejiang Cancer Hospital | 2019-08-15 |
| Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (NCT03786796) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2019-06-03 |
| UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade (NCT03474497) | Megan Daly, MD | 2019-05-20 |
| CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer (NCT03829111) | City of Hope Medical Center | 2019-05-14 |
| Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies (NCT03408652) | Centre Leon Berard | 2019-03-15 |
| Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 (NCT03284385) | National Cancer Institute (NCI) | 2019-01-29 |
| Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors (NCT03682289) | Rahul Aggarwal | 2019-01-17 |
| NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy (NCT03589339) | Nanobiotix | 2019-01-16 |
| A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) (NCT03595124) | National Cancer Institute (NCI) | 2019-01-08 |
| A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) (NCT03729245) | Nektar Therapeutics | 2018-12-18 |
| Prospective Translational Study Investigating Predictors of Outcome in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab (I-Rene Trial) (NCT04891055) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2018-11-29 |
| INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma (NCT03692338) | Duke University | 2018-11-19 |
| Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment. (NCT03647878) | Ipsen | 2018-09-24 |
| Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib (NCT04076787) | Pfizer | 2018-09-01 |
| Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer (NCT03587662) | M.D. Anderson Cancer Center | 2018-08-17 |
| Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma (NCT03575611) | M.D. Anderson Cancer Center | 2018-06-14 |
| A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma (NCT03463681) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2018-06-11 |
| Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma (NCT03541902) | M.D. Anderson Cancer Center | 2018-05-15 |
| CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma (NCT03428217) | Calithera Biosciences, Inc | 2018-04-24 |
| Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab (NCT03149159) | Medical University of South Carolina | 2018-04-01 |
| Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion (NCT03494816) | Scottish Clinical Trials Research Unit | 2017-12-15 |
| Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment (NCT03200717) | Novartis Pharmaceuticals | 2017-11-14 |
| Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC (NCT03075423) | Goethe University | 2017-11-01 |
| Impact of the PRISM-care Multidisciplinary Oncology Program on Secured Drug Intake of Patients With Kidney Cancer (NCT02849535) | Hospices Civils de Lyon | 2017-10-17 |
| Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma (NCT03149822) | University of Colorado, Denver | 2017-09-28 |
| Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy. (NCT03140176) | Pfizer | 2017-08-15 |
| M8891 First in Human in Solid Tumors (NCT03138538) | EMD Serono Research & Development Institute, Inc. | 2017-08-08 |
| Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab (NCT03126331) | Case Comprehensive Cancer Center | 2017-08-03 |
| Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment (NCT02789137) | Pfizer | 2016-12-22 |
| Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib (NCT03091465) | Spanish Oncology Genito-Urinary Group | 2016-12-20 |
| Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy (NCT03891485) | National Cancer Institute, Naples | 2016-12-01 |
| TIL Therapy for Metastatic Renal Cell Carcinoma (NCT02926053) | Inge Marie Svane | 2016-12-01 |
| Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor (NCT02944617) | City of Hope Medical Center | 2016-11-11 |
| PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma. (NCT02867332) | Peking University | 2016-11-01 |
| A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers (NCT03115801) | Weill Medical College of Cornell University | 2016-11-01 |
| Second Line Sorafenib After Pazopanib in Patients With RCC (NCT02122003) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2016-09-01 |
| Safety and Preliminary Efficacy of SBRT in Patients With Metastatic RCC Treated With Targeted or IO Therapy (NCT02864615) | Kidney Cancer Research Bureau | 2016-08-01 |
| A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma (NCT02837991) | Celldex Therapeutics | 2016-06-01 |
| Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery (NCT02595918) | National Cancer Institute (NCI) | 2016-05-19 |
| A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma (NCT02639182) | Astellas Pharma Global Development, Inc. | 2016-05-03 |
| A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients. (NCT02774200) | Tianjin Medical University Cancer Institute and Hospital | 2016-05-01 |
| Testosterone in Metastatic Renal Cell Carcinoma Patients (NCT03379012) | Kidney Cancer Research Bureau | 2016-02-08 |
| Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen (NCT03013335) | UNICANCER | 2016-01-01 |
| Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors (NCT02599324) | Pharmacyclics LLC. | 2015-12-01 |
| Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC) (NCT02447887) | Fox Chase Cancer Center | 2015-08-14 |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (NCT02419495) | M.D. Anderson Cancer Center | 2015-06-26 |
| Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb (NCT04462445) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2015-06-25 |
| Immunotherapy Study for Metastatic Renal Cell Cancer (NCT02035358) | NewLink Genetics Corporation | 2015-05-01 |
| Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (NCT02298959) | National Cancer Institute (NCI) | 2015-04-08 |
| Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets (NCT02406521) | Dana-Farber Cancer Institute | 2015-04-01 |
| A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma. (NCT02398552) | Peking University Cancer Hospital & Institute | 2015-03-01 |
| Interleukin-2-Induced Cognitive/Affective/Sleep Symptoms (NCT02150369) | Duke University | 2015-02-16 |
| Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients (NCT02330783) | Peking University Cancer Hospital & Institute | 2014-12-01 |
| Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma (NCT03519542) | Spanish Oncology Genito-Urinary Group | 2014-11-01 |
| Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) (NCT02231749) | Bristol-Myers Squibb | 2014-10-16 |
| Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy (NCT02282579) | Spanish Oncology Genito-Urinary Group | 2014-10-01 |
| CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) (NCT02187302) | NewLink Genetics Corporation | 2014-07-01 |
| Functional Imaging in the Assessment of mRCC Response to Sunitinib (NCT01977586) | Imperial College Healthcare NHS Trust | 2014-04-01 |
| RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017) (NCT02026960) | Duke University | 2014-03-01 |
| Optimizing Pazopanib Exposure in RCC Patients (NCT02089802) | Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e. | 2014-02-25 |
| A Retrospective Real World Analysis Of Sutent In Patients With Metastatic Renal Cell Carcinoma In Community And Academic Centers To Assess The Impact Of Dose Variation On Duration Of Response And Overall Survival (NCT01917214) | Pfizer | 2013-08-01 |
| Sutent Rechallenge In mRCC Patients (NCT01827254) | Pfizer | 2013-07-01 |
| Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer (NCT01784978) | Associació per a la Recerca Oncologica, Spain | 2013-02-12 |
| Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma (NCT02071641) | Amsterdam UMC, location VUmc | 2012-10-01 |
| A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC (NCT01673386) | AVEO Pharmaceuticals, Inc. | 2012-07-01 |
| Pazopanib in Second-line Therapy in Renal Cell Carcinoma (NCT01577784) | Associació per a la Recerca Oncologica, Spain | 2012-04-01 |
| Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC) (NCT01550367) | Leonard Appleman | 2012-03-01 |
| A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer (NCT01525017) | Mendus | 2012-02-01 |
| Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors (NCT01482156) | Novartis Pharmaceuticals | 2012-01-01 |
| Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases (NCT01444807) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2011-12-01 |
| PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma (NCT01441414) | Pfizer | 2011-11-21 |